Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
Business Wire
Apimeds Pharmaceuticals US settles with Inscobee. The settlement lets the MindWave merger proceed and the $100 million PIPE financing close.
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a settlement that resolves the outstanding merger-related disputes with Inscobee.
The settlement clears the path for the MindWave merger transactions to proceed and for the previously disclosed $100 million PIPE financing to close.
The release also states that Lōkahi Therapeutics advances the Apitox program.
